Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis

Intensive Care Medicine
P G Berthelsen

Abstract

In patients with metabolic alkalosis, compensatory alveolar hypoventilation may induce hypercapnia and hypoxemia. In edematous or normally-hydrated patients without electrolyte deficiencies, acetazolamide--a carbonic anhydrase inhibitor--has been advocated to correct the primary acid-base disturbance, thereby preventing hypoxemia. The hemodynamic consequences and the effect on oxyhemoglobin dissociation of acetazolamide, were studied. Twelve critically ill patients with metabolic alkalosis were given 15 mg/kg body wt. acetazolamide intravenously. Cardiovascular performance was completely unchanged. The P50 was 26.6 mm Hg at the beginning and the end of the study, indicating that hemoglobin-oxygen affinity is unaffected by acetazolamide. In six patients, investigated after open-heart surgery, the arterial oxygen tension increased by 10-45%. This was probably related to the combined effects of slight reductions in total body oxygen consumption or shunting of venous blood through the lungs. Eight of the 12 patients were on controlled ventilation. After acetazolamide there was a mean increase in mixed venous carbon dioxide tension (PvCO2) of 4.5 mm Hg, with no increase in arterial carbon dioxide tension (PaCO2), indicating only a l...Continue Reading

References

Jan 10, 2004·The Journal of Laboratory and Clinical Medicine·Xuefeng GaiHisayo Nagaishi
Aug 8, 2012·Critical Care : the Official Journal of the Critical Care Forum·Nicholas HemingChristophe Faisy
Jan 20, 2006·Critical Care : the Official Journal of the Critical Care Forum·Miriam MoviatJohannes G van der Hoeven
Dec 30, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Tze-Kai WangMingli Hsieh
Mar 1, 1992·The Journal of Pediatrics·D A BenaronP A Dennery
Mar 27, 2015·International Journal of Critical Illness and Injury Science·Mabrouk BahloulMounir Bouaziz
Jan 24, 2018·The Annals of Pharmacotherapy·Jason D GuffeyDavid C Kaufman
Jun 4, 2019·Journal of Neuroscience Research·Mingli HsiehChe-Min Lo
Jan 1, 1987·Intensive Care Medicine·P G Berthelsen, J O Dich-Nielsen

Citations

Jan 1, 1976·British Journal of Haematology·M A LichtmanM Pogal
Jul 1, 1979·Southern Medical Journal·T J Gallagher
Dec 13, 1979·The New England Journal of Medicine·J R SuttonA C Powles
Nov 28, 1977·JAMA : the Journal of the American Medical Association·P D Miller, A S Berns
Aug 1, 1977·British Journal of Anaesthesia·L I Worthley
Mar 18, 1972·Lancet·M H TattersallA S Spiers
Sep 19, 1968·The New England Journal of Medicine·W B SchwartzJ P Kassirer
Feb 1, 1972·Chest·T M JarboeR G Luke
Aug 1, 1972·Archives of Surgery·R F WilsonC Lucas
Nov 1, 1971·Scandinavian Journal of Clinical and Laboratory Investigation·G Rooth, L Jacobson
Mar 1, 1971·The American Journal of Medicine·M A Tuller, F Mehdi
Dec 1, 1980·Critical Care Medicine·J E HodgkinD M Chan
Nov 1, 1961·Journal of Applied Physiology·S M CAIN, A B OTIS
Jan 1, 1968·The Journal of Clinical Investigation·R M GoldringA P Fishman

Related Concepts

Dioxygen
Acetazolamide Sodium, (Sterile)
Cardiovascular Diseases
Hypercapnia
Idiopathic Pulmonary Hemosiderosis
Hemodynamics
Oxyhemoglobin
Carbon Dioxide
CA1
Hydrogen-Ion Concentration

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.